Category: News
Organizational, research, and community announcements. Posts in this category appear automatically on the Latest News page.
-
This Landmark HHT Study Could Shift National Attention
We’re excited to share some truly important news for the HHT community. A major new study done in collaboration between Cure HHT, Massachusetts General…
-
A Major Step Forward for HHT Treatment: Promising Preclinical Data from Diagonal Therapeutics
We’re excited to share two important updates from our partners at Diagonal Therapeutics. At this week’s European Hematology Association (EHA) Congress, Diagonal Therapeutics presented promising…
-
Diagonal Therapeutics Initiates Natural History Study of Adults Living with Hereditary Hemorrhagic Telangiectasia (HHT), a Rare Bleeding Disorder with No Approved Treatments
Diagonal Therapeutics Initiates Natural History Study of Adults Living with Hereditary Hemorrhagic Telangiectasia (HHT), a Rare Bleeding Disorder with No Approved Treatments Study conducted…
-
Innovative Hematology Achieves Prestigious HHT Center of Excellence Certification
We are thrilled to share that Innovative Hematology, home to the Indiana Hemophilia and Thrombosis Center (IHTC), has officially earned the coveted designation as…
-
Important FDA Update Regarding Iron Infusions
There’s been a change to the safety label for Injectafer®, an iron infusion often used to treat iron deficiency. The FDA now includes HHT…
-
Press Release: Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of HHT
Diagonal Therapeutics — who has raised $128 million in Series A funding to support their sole project, a curative HHT therapy — today issued…
-
Press Release: Vaderis Receives FDA Fast Track Designation for Treatment of HHT
The below press release was issued Monday, Nov. 18 by Vaderis Therapeutic, and is substantial news for our community. Cure HHT has worked hand-in-hand with leadership…
-
Press Release: Cure HHT Plays Key Role in First Successful HHT Trial
We’re thrilled to share some important news from the world of HHT research. The National Institutes of Health-sponsored PATH trial is complete, the results are in,…
-
A Monumental $128 Million Step Forward for HHT Research
Today is a monumental day for HHT. The new biotechnology company, Diagonal Therapeutics, officially launched and we wanted to share more about why this…
-
A major milestone for HHT treatment!
I am reaching out to share the news of a truly momentous milestone for both our organization and our community; the Pazopanib clinical trial…